T Cell Costimulatory and Coinhibitory Pathways in Vascular Inflammatory Diseases

DSpace/Manakin Repository

T Cell Costimulatory and Coinhibitory Pathways in Vascular Inflammatory Diseases

Show simple item record

dc.contributor.author Lichtman, Andrew Harry
dc.date.accessioned 2012-04-25T17:35:13Z
dc.date.issued 2012
dc.identifier.citation Lichtman, Andrew H. 2012. T cell costimulatory and coinhibitory pathways in vascular inflammatory diseases. Frontiers in Physiology 3: 18. en_US
dc.identifier.issn 1664-042X en_US
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:8615965
dc.description.abstract A broad array of evidence indicates that T lymphocytes make significant contributions to vascular inflammation in the setting of atherosclerotic disease, hypertension, autoimmune vasculitis, and other disorders. Experimental data show that costimulatory and coinhibitory pathways involving molecules of the B7-CD28 and TNF–TNFR families regulate T cell responses that promote vascular disease. Antigen presenting cells (APCs) display both peptide–major histocompatibility complex antigen and costimulators or coinhibitors to T cells. Two major types of APCs, dendritic cells (DCs) and macrophages, are present in significant numbers in the walls of arteries affected by atherosclerosis and arteritis, and some DCs are present in normal arteries. Costimulatory and coinhibitory molecules expressed by these vascular APCs can contribute to the activation or inhibition of effector T cells within the arterial wall. Vascular DCs may also be involved in transport of antigens to secondary lymphoid organs, where they activate or tolerize naïve T cells, depending on the balance of costimulators and coinhibitors they express. Costimulatory blockade is already an approved therapeutic approach to treat autoimmune disease and prevent transplant rejection. Preclinical models suggest that costimulatory blockade may also be effective in treating vascular disease. Experiential data in mice show that DCs pulsed with the appropriate antigens and treated in a way that reduces costimulatory capacity can reduce atherosclerotic disease, presumably by inducing T cell tolerance. Progress in treating vascular disease by immune modulation will require a more complete understanding of the functions of different costimulatory and coinhibitory pathways and the different subsets of vascular APCs involved. en_US
dc.language.iso en_US en_US
dc.publisher Frontiers Research Foundation en_US
dc.relation.isversionof doi:10.3389/fphys.2012.00018 en_US
dc.relation.hasversion http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280481/pdf/ en_US
dash.license LAA
dc.subject costimulation en_US
dc.subject coinhibition en_US
dc.subject macrophages vascular disease en_US
dc.subject dendritic cells en_US
dc.subject atherosclerosis en_US
dc.subject T cells en_US
dc.title T Cell Costimulatory and Coinhibitory Pathways in Vascular Inflammatory Diseases en_US
dc.type Journal Article en_US
dc.description.version Version of Record en_US
dc.relation.journal Frontiers in Physiology en_US
dash.depositing.author Lichtman, Andrew Harry
dc.date.available 2012-04-25T17:35:13Z

Files in this item

Files Size Format View
3280481.pdf 3.372Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters